Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Johnson & Johnson posts Q3 beat
Johnson & Johnson posts Q3 beat; lowers earnings guidance amid M&A impact
Johnson & Johnson (NYSE:JNJ) lowered its full-year earnings outlook on Tuesday despite posting better-than-expected financials for Q3 2024, driven mainly by its pharma unit even as its MedTech division fell short of forecasts.
Johnson & Johnson’s stock falls despite Q3 sales beat and guidance raise
Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.
Johnson & Johnson: Strong Q3 Performance and Upward Sales Guidance Bolster Buy Rating
Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The associated
Fiscal Q3 Earnings Snapshot
Banner: Q3 Earnings Snapshot
The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.18 per share. The regional bank posted revenue of $213.9 million in the period. Its adjusted revenue was $153.
Kinder Morgan: Q3 Earnings Snapshot
Kinder Morgan Inc. (KMI) on Wednesday reported third-quarter net income of $625 million. On a per-share basis, the Houston-based company said it had net income of 28 cents. Earnings, adjusted for non-recurring gains,
Johnson & Johnson: Q3 Earnings Snapshot
Johnson & Johnson expects full-year earnings in the range of $9.88 to $9.98 per share, with revenue in the range of $88.4 billion to $88.8 billion. This story was generated by Automated Insights ( http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ
25m
What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
2d
on MSN
Johnson & Johnson Q3 Preview: Decline in profit is in the cards
Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 15th, before market open.
16h
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
6d
What Trends Will Drive Johnson & Johnson's Q3 Results?
We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus ...
1d
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4 ...
The Motley Fool
1d
Johnson & Johnson Q3 EPS Dips on Charges
In
Q3
2024,
Johnson
&
Johnson
's innovative medicine segment reported a 6.3% operational sales growth, with oncology and immunology products leading the way. Substantial demand for Darzalex and ...
18h
Johnson & Johnson’s Growth Potential Highlighted by Strong Q3 Earnings and Promising Pipeline
David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...
MM&M
1d
J&J reports Q3 sales surge of 5.2% despite EPS decline due to M&A activity
Despite the topline growth, J&J’s net earnings fell 37.5% to $2.6 billion, down from $4.3 billion in Q3 2023. Johnson & ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback